Models on the rate of sexual debut among opportunistic vaccinees were initially restricted to women age 18–37 years at response, corresponding to the age range of opportunistic pre-debut vaccinees. Similarly, all models addressing the effect of organized vaccination were restricted to women age

18–19 years at response. Non-significant model terms were removed by MLN0128 backwards deletion, and alternative models were compared by likelihood ratio tests. We also assessed models by diagnostic plots. We report the best fitting model containing the vaccine-status variable. All tests were two-tailed, with a 0.05 α-level. Statistical computing was done with R software [29]. The participation rate was highest in Denmark (75.1%), and most women responded via the paper questionnaire (Table 1). The participation rate was somewhat higher in the Dinaciclib clinical trial older age groups, and among women who had attained higher education and income. Participants were also more frequently married and less frequently immigrants than were

non-participants (Appendix, Table A.2–A.4). The number of vaccinees was lower in Norway (n = 161) than in Denmark (n = 2508) and Sweden (n = 1057). The officially reported uptake rates for at least one dose of the HPV vaccine among women eligible for organized catch-up vaccination is 87% [30]. Similarly, 87% of the women of the corresponding cohort who participated in the current survey reported that they ever

had received the HPV vaccine. The rates of sexual debut were similar for women who were vaccinated against HPV before sexual debut and unvaccinated women (Fig. 1), and did not differ significantly (Table 2). This held true for opportunistic (adjusted hazard ratio (95%CI): 0.94 (0.88; 1.02)) as well as organized vaccinees (0.88 (0.76; 1.01)). Restricting the model of opportunistic vaccination to 18–24 found years olds gave a similar result (1.07 (0.99; 1.16)). Hence, the age at first intercourse was similar for women who were vaccinated and women who were not vaccinated against HPV. The number of sexual partners was not significantly higher among women vaccinated against HPV prior to sexual debut than among matched unvaccinated women. Organized vaccinees did not differ significantly from non-vaccinees in terms of number of sexual partners before age 18 or lifetime number of partners (Table 3). Opportunistic vaccinees did not differ from non-vaccinees in terms of lifetime number of partners (Table 4), but were significantly less likely than non-vaccinees to have had four or more partners before reaching age 18 (adjusted odds ratio (95%CI): 0.56 (0.40; 0.78); Table 4). At the one and two partner cutpoints, opportunistically vaccinated and unvaccinated women did not differ significantly in the number of partners before age 18 (Table 4).